Prime Medicine Inc. (PRME) News
Filter PRME News Items
PRME News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRME News Highlights
- For PRME, its 30 day story count is now at 2.
- Over the past 19 days, the trend for PRME's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GENE and PRE are the most mentioned tickers in articles about PRME.
Latest PRME News From Around the Web
Below are the latest news stories about PRIME MEDICINE INC that investors may wish to consider to help them evaluate PRME as an investment opportunity.
Better Growth Stock: Archer Aviation or Prime Medicine?Which of these innovation-themed growth stocks is the better buy? |
1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 YearsCathie Wood, founder and CEO of Ark Invest, has a unique approach to investing. As a result, she hasn't hesitated to buy shares of early-stage innovation companies well ahead of the Wall Street crowd. Wood has been purchasing shares of the pre-clinical gene-editing company for her ARK Genomic Revolution ETF (NYSEMKT: ARKG) since the company's initial public offering (IPO) in October of 2022. |
Prime Medicine to Present at Upcoming Investor ConferencesCambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company management will present at two upcoming investor conferences: Stifel Healthcare Conference: Fireside Chat by Keith Gottesdiener, M.D., President and Chief Executive Officer, on Tuesday, November 14, 2023, at 4:10 p.m. ET in New York, NY.Jefferies London Healthcare C |
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile -- -- Received U.S. FDA Rare Pediatric Drug designation for PM359 for CGD; initiated IND-enabling st |
Top 20 Genomics Companies in the WorldIn this piece, we will take a look at the top 20 genomics companies in the world. If you want to skip our analysis of the genomics industry, then take a look at the Top 5 Genomics Companies in the World. Modern day science has delivered a plethora of advancements that have enabled humans to […] |
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1bUp to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well Above Anticipated Threshold Necessary to Reverse Disease Manifestations Up to 56% Whole Liver Editing Observed in Humanized GSD1b Mouse Model No Detectable Off-target Edits Observed Following Comprehensive in vitro Analysis Data Presented Today in an Oral Presentation at ESGCT 2023 CAMBRIDGE, Mass., Oct. 27, 2023 (GLO |
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological DiseasesNew In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at RHO p.P23H Mutation and up to 65% at RHO p.V345L and p.P347L, Well Above Threshold Required to Stop Disease Progression in Photoreceptors No Detectable AAV Genome Integration and No Detectable Off-target Edits Observed Data Presented Today in an Oral Presentation at RD2023 CAMBRIDGE, Mass., Oct. 24, 2 |
‘The Bull Market Can Continue to Roll On;’ BMO’s Brian Belski Predicts Further Gains for Stocks — Here Are 3 Names to Play That Bullish SentimentWe recently passed an anniversary, of sorts – one year to the day since the stock market hit bottom. On October 12 of last year, the S&P 500 reached its trough; since then, the market trend has been upward despite some volatility and a recent pullback. Brian Belski, chief investment strategist from BMO Capital, believes that we’re into a secular bull market now. Looking at a series of factors – general economic growth, the slowing pace of inflation, the stage of the Fed’s monetary policy, Belski |
7 Biotech Stocks to Get In Now Before Investors Catch OnBiotech stocks are down, but there are hidden gems among the rubble. |
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry ConferencesCAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Company will showcase advances in preclinical data across the Prime Editing pipeline and platform at several healthcare industry conferences in October and November 2023. “We are pleased to share new preclinical research across our programs, including proof-of-concept da |